Q3 2026 Shalby Ltd Earnings Call Transcript
Key Points
- Shalby Ltd (BOM:540797) reported a significant improvement in consolidated PAT, showing a positive margin of 0.5% in Q3 FY26 compared to a negative margin of 1.1% in Q3 FY25.
- The company maintains a strong balance sheet with a low gearing ratio of 0.41x and a net debt of INR408 crores.
- Shalby MedTech reported a 29% year-on-year growth in consolidated revenue for Q3 FY26, driven by strong domestic execution and improved distribution reach.
- The MedTech division achieved a positive EBITDA of INR0.7 million, marking a significant turnaround from a loss of INR69 million in Q3 FY25.
- Shalby Ltd has successfully completed 32 transplants, including 29 kidney transplants and 3 liver transplants, showcasing its clinical excellence.
- Consolidated revenue for Q3 FY26 was marginally down by 0.6% year-on-year, indicating a slight decline in overall business performance.
- The stand-alone EBITDA margin decreased from 21.5% in Q3 FY25 to 16% in Q3 FY26, reflecting a decline in profitability.
- Occupancy rates have decreased, with the group level occupancy rate standing at 47% in Q3 FY26 compared to 48% in Q3 FY25.
- The company faced challenges with insurance work, leading to a temporary halt in operations with major insurance companies, impacting patient volumes.
- Shalby Ltd experienced a net loss of doctors, with 18 doctors leaving despite hiring 40 new doctors, affecting the continuity of care and patient volumes.
Ladies and gentlemen, good day, and welcome to Shalby Limited Q3 FY26 earnings conference call, hosted by Elara Securities Private Limited. (Operator Instructions). Please note that this conference is being recorded.
I now hand the conference over to Mr. Kashish Thakur. Thank you, and over to you, sir.
()-
Thank you, Anurag. Good afternoon, everyone. We welcome all the participants to Shalby Limited Q3 and nine months FY26 earnings conference call, hosted by Elara Securities.
Today, we have with us senior management representative from Shalby. We will start with the performance highlights from Group CFO of Shalby Limited, Mr. Amit Kumar; and Mr. Deepak Anand, Chief Executive Officer of Shalby MedTech. After that, we will open the floor for question-and-answers for all the participants.
I will now hand over the call to Mr. Jigar Todi for important disclaimers regarding any forward-looking statements that may be made in today's call.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
